arrow
P

Pamela S. Ohashi

princess margaret cancer centre
H指数:111
被引数:5.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Identification of broadly tumour-reactive γδ TCRs from multiple myeloma

从多发性骨髓瘤中鉴定广谱肿瘤反应性γδ TCRs

Nature
IF48.5
2026-09-160
OAAI
Novel lipid nanoparticle in a mRNA cancer vaccine drives tumor control via type I IFNs and effector CD8+ T cells

新型脂质纳米颗粒在mRNA癌症疫苗中通过I型IFNs和效应性CD8+ T细胞驱动肿瘤控制

2026-08-270
OA
Life Years Gained and Healthcare Dollars Saved: National Economic Evidence Supporting Comprehensive Genomic Profiling as Standard of Care for Canadian Cancer Patients

生命年获得与医疗费用节省:支持将综合基因组分析作为加拿大癌症患者标准治疗的国家经济证据

2026-04-040
OAAI
Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab

一种组织无关的全基因组甲基组富集检测的临床验证,用于监测帕博利珠单抗的治疗反应

2026-02-130
OAAI
Guidelines for T cell nomenclature

T细胞命名指南

2025-11-180
OAAI
Intratumoural CD103+CD56+ILCs are associated a with dysfunctional CD8+T cell profile in patients with ovarian epithelial carcinoma
2025-11-010
PRE
A retrospective analysis exploring the association of pretreatment neutrophil-to-lymphocyte ratio and immune checkpoint inhibitor outcomes in patients with advanced NSCLC and liver metastases

一项回顾性分析,探讨治疗前中性粒细胞与淋巴细胞比值与晚期非小细胞肺癌伴肝转移患者免疫检查点抑制剂疗效的关联。

2025-10-220
OA
T cell receptor repertoire in cell-free DNA as a proxy for tumor infiltrates in patients treated with pembrolizumab

细胞外DNA中的T细胞受体库作为接受帕博利珠单抗治疗患者肿瘤浸润细胞的替代标志物

2025-08-270
PREAI
Cholinergic regulation of thymocyte negative selection

胆碱能调控对胸腺细胞阴性选择的影响

2025-05-210
PRE
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Terry Fox Research Institute马拉松希望癌症中心网络:一项全加拿大的精准肿瘤学倡议

2025-04-010
PRE
TRANSLATING COMBINED PD1 AND LAG3 INHIBITION FROM PRECLINICAL MODELS TO PATIENTS WITH REFRACTORY, DNA REPLICATION REPAIR DEFICIENT (RRD) GLIOBLASTOMA: AN IRRDC STUDY
2024-11-110
PRE
COMBINED PD1 AND LAG3 INHIBITION IN PRECLINICAL MODELS AND PATIENTS WITH DNA REPLICATION REPAIR DEFICIENT GLIOBLASTOMA (RRD-GBM): AN IRRDC STUDY
2024-06-180
OAAI